NOVARTIS AG-SPONSORED ADR (NVS) Stock News
NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR - Currency: USD
NVS Latest News, Press Relases and Analysis
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio.
Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO
Novartis Strikes Up to $3.1 Billion Deal to Buy Anthos Therapeutics
Novartis (NVS) on Tuesday agreed to acquire biopharmaceutical firm Anthos Therapeutics in a deal wor
Novartis agrees to acquire Anthos for up to $3.1 billion
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant. The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential additional payment of up to $2.15 billion, the company said.
Novartis to Buy Anthos Therapeutics for $925 Million
Novartis AG has agreed to acquire Anthos Therapeutics for $925 million as the European drug giant seeks to bolster its late-stage cardiovascular pipeline.
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Mentions: BMY
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2024.
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.
Novartis has cash for a big pharma deal—but here’s why it’s not buying
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on acquisitions in 2025.
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
The company's biggest moneymaker is expected to face off with lower-cost generics this summer.
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance.
Novartis beats consensus on Q4 earnings
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues. Fourth-quarter net income, adjusted for special items, rose 26% to $3.93 billion, the Swiss drugmaker said in a statement, surpassing an analyst consensus of $3.64 billion, according to LSEG data.
Novartis Sees Profit Gaining Despite Copycats for Top Drug
Novartis AG said profit will rise this year as new medicines help offset the competition it expects from copycats of its best-selling medicine.
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.